Oligonucleotide therapeutics are evolving beyond the early generation of antisense oligonucleotides (ASOs). Today, developers are working with a diverse set of modalities, including small interfering RNAs (siRNAs), splice-switching oligonucleotides, editing approaches, and sophisticated conjugated molecules designed to reach specific tissues and cell types.
This rapid innovation is expanding the therapeutic potential of nucleic acid-based medicines. At the same time, it is fundamentally changing how developers approach preclinical development.
Historically, many oligo programmes followed a relatively similar nonclinical strategy. Safety assessment, pharmacokinetic (PK) characterisation, and species selection often relied on established frameworks that could be applied across multiple candidates. However, as modalities have become more specialised, developers can no longer assume that a standard development package will adequately characterise a new therapeutic.
Instead, the field is moving toward modality-specific, risk-based approaches that account for delivery technologies, tissue targeting, chemical modifications, and mechanism of action. As a result, preclinical development is becoming increasingly tailored to the unique characteristics of each programme.
The End of the One-Size-Fits-All Development Strategy
Over the past decade, oligo therapeutics have continued to get more complex, requiring a shift in regulatory expectations and scientific understanding. Rather than treating all oligos similarly, developers must justify testing strategies based on the specific characteristics of the modality being evaluated because the reality is, not all oligos behave the same way.
Differences in stereochemistry, chemical backbone modifications, target engagement mechanisms, and delivery approaches can impact efficacy, safety, biodistribution, and translational relevance. As a result, platform-based development strategies can use prior knowledge from established chemistries, but novel modalities often require customised assessments to address unique risks.
The result is a departure from the traditional "one-size-fits-all" mindset toward a more data-driven framework where testing requirements are determined by scientific evidence and modality-specific considerations.
Delivery Technologies Are Reshaping Development
Perhaps no factor has had a greater impact on oligonucleotide development than advances in delivery technology.
Early oligo programmes often relied on relatively simple formulations. Today, developers have access to a growing toolbox that includes lipid nanoparticles (LNPs), ligand conjugates, peptide-based delivery systems, and other targeted approaches designed to improve cellular uptake and tissue specificity.
These technologies can dramatically alter where a therapeutic accumulates, how long it persists in tissues, and the magnitude of its biological activity.
For example, GalNAc conjugation has transformed liver-targeted oligonucleotide delivery by enabling efficient hepatocyte uptake. Peptide-based approaches are being explored to improve delivery to tissues that have historically been difficult to reach, while specialised formulations are helping advance programmes targeting the central nervous system and other protected tissues.
In many cases, delivery chemistry may influence therapeutic performance as much as—or even more than—the oligo sequence itself. Conjugation strategies can affect organ distribution, cellular uptake, potency, and safety profiles. They may also introduce linker stability, carrier-related toxicities, and immunogenicity risks.
As a result, evaluating the delivery platform has become an essential component of modern oligonucleotide development rather than a secondary formulation consideration.
Biodistribution Has Become a Central Development Question
As delivery technologies become more sophisticated, understanding biodistribution is one of the most important objectives of preclinical development.
Biodistribution directly influences therapeutic index by determining whether a drug reaches its intended target tissue while minimising exposure to non-target organs. It affects efficacy, safety, dose selection, route of administration, and clinical monitoring strategies.
For many oligo therapeutics, tissue exposure may provide more meaningful information than plasma PK alone. Long tissue residence times can create sustained pharmacologic activity but may also increase the risk of accumulation-related toxicities.
Several tissues continue to present development challenges:
• The blood-brain barrier limits access to the central nervous system.
• Muscle, heart, eye, and bone marrow remain difficult to target efficiently.
• Kidney accumulation may contribute to both therapeutic benefits and safety concerns.
This has led developers to integrate biodistribution studies early in development to better understand target engagement, optimise dosing strategies, and anticipate potential safety liabilities.
Safety Assessment Is Becoming More Mechanism-Specific
The diversification of oligonucleotide modalities is also reshaping safety evaluation.
Some safety considerations continue to require careful assessment: hybridisation-dependent off-target effects, innate immune activation, nuclease-mediated degradation, and tissue accumulation. However, many emerging risks are becoming increasingly modality specific.
For example, certain gapmer ASOs may be associated with hepatotoxicity linked to RNase H1-mediated mechanisms. siRNA programmes may require evaluation of passenger-strand-related effects. Conjugated molecules can introduce new considerations related to receptor saturation, carrier biology, or immunogenicity. Emerging editing technologies may raise concerns about unintended editing events and off-target activity.
This evolution is driving a broader shift away from generalised safety checklists and toward mechanism-based evaluation strategies that focus on the unique biological properties of each modality. The goal is not necessarily to perform more testing, but to perform the right testing based on the risks most relevant to the therapeutic under investigation.
Bioanalysis and Translation Are Growing More Complex
As oligo architectures become more sophisticated, bioanalytical requirements grow more challenging.
Many modern therapeutics exist as multiple molecular species, including intact conjugates, released oligonucleotides, metabolites, carrier components, and degradation products. Understanding the relationships among these species is critical for accurately characterising exposure and biological activity.
Developers must often quantify multiple analytes while addressing challenges in tissue extraction, metabolite identification, and the analysis of low-abundance species. Fit-for-purpose assay development has become essential for generating data that support regulatory decision-making and clinical translation.
Species selection is another challenge. Traditional approaches that relied on a relatively limited set of animal models are being augmented by more nuanced evaluations that consider target homology, receptor expression, immune compatibility, route feasibility, and translational relevance.
In some cases, surrogate molecules may be required to evaluate pharmacology or safety in nonclinical models. In others, species-specific biology may complicate the interpretation of efficacy or toxicity findings.
Here, we see a broader trend emerging: successful translation depends on understanding the complex interplay among chemistry, delivery, biology, and analytical strategy.
Looking Ahead: The New Oligo Playbook
The pace of innovation in oligonucleotide therapeutics shows little sign of slowing. Emerging technologies such as RNA editing, extrahepatic delivery platforms, novel conjugation approaches, sequence design are expected to expand the range of treatable diseases.
These advances will likely create new opportunities—and new development challenges.
As the field continues to mature, preclinical programmes must become more individualised. Rather than relying on standardised testing packages, developers need to build scientifically justified strategies that account for the unique characteristics of each modality, delivery platform, and therapeutic target.
The future of oligo development will depend on integrating delivery, biodistribution, safety assessment, bioanalysis, and translational science into a cohesive, modality-specific development strategy.
Read the full article — it's free
Register with Pharma Focus America to unlock expert insights, research articles and in-depth industry analysis.
